Quantitative screening

Move from pathway insight to transparent first-pass calculations.

Run a lightweight budget-impact, price benchmark, IRP linkage and renewal scenario, then hand structured parameters to a validated HEOR model.

Target marketIndicationBase currency

South KoreaSingle national positive list

Three-year budget impact

New therapy uptake replaces the comparator for the treated cohort.

Eligible patients, year 1Annual population growth (%)Price per unitUnits per patient / yearComparator annual costOther annual cost delta

Year 1 uptake (%)Year 2 uptake (%)Year 3 uptake (%)

Preliminary result

$0

Cumulative three-year incremental budget impact

Year 1$01,000 treated patients

Year 2$02,000 treated patients

Year 3$03,000 treated patients

Uptake sensitivity ±20%$0 — $0

Method noteThe BIA is a transparent cost-calculator structure. Use a cohort or patient-level model when population entry and exit, disease severity, treatment switching, mortality or adverse events materially change results. Validate inputs against the target payer and local submission guidance.

Method references

ISPOR · Budget Impact Analysis Principles of Good Practice European Commission · External reference pricing coordination TreeAge · Connecting TreeAge and Excel